Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy
Jingyi Li(Fujian Medical University), Minghui Zhao(Sunnybrook Health Science Centre), Helen Monaghan(The George Institute for Global Health), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), Alan Cass(University of Sydney), Vlado Perkovic(New South Wales Department of Health), M.G. Wong(The University of Sydney), Vivekanand Jha(The George Institute for Global Health), Mark Woodward(UNSW Sydney), David W. Johnson(Hennepin County), Muh Geot Wong(FIND), Sufang Shi, Heather N. Reich(University Health Network), John Feehally(University of Leicester), Tak Mao Chan(Chinese University of Hong Kong), Jincan Zan(Peking University), David C. Wheeler(University College London), Jicheng Lv(Ministry of Education of the People's Republic of China), Richard J. Glassock(University of California, Los Angeles), Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Hong Zhang(Peking University), Meg Jardine(Royal North Shore Hospital), Adeera Levin(University of British Columbia), Yangfeng Wu(Peking University), Daniel C. Cattran(Toronto Rehabilitation Institute), Lai Seong Hooi(Sultanah Aminah Hospital), Sean Barbour, Michelle Hladunewich(Sunnybrook Health Science Centre)
Cited by 28
Related Papers
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k